Abstract
Background: Stereotactic radiosurgery (SRS) plays a significant role in the treatment of various benign and malignant tumors of the central nervous system. Recently, the first self-shielding treatment platform for gyroscopic radiosurgery (GRS) was introduced. Herein, we report our experience with GRS treatment of the first 541 tumors in a prospective setting.
Materials and methods: This study enrolled patients who underwent GRS for intracranial tumors. Patient, treatment, and outcome data were prospectively collected and analyzed. Only patients with at least one imaging and clinical follow-up were included in this analysis. Volumetric assessments and major toxicity are presented.
Results: A total of 491 patients were treated between 2021 and 2024. Of those, 382 patients harboring 541 tumors underwent at least one imaging and clinical follow-up. The majority of tumor entities treated were vestibular schwannomas (196), brain metastases (188), and meningiomas (113). The median prescription dose for brain metastases was 20 Gy. For meningiomas and vestibular schwannomas, the median prescription doses were 15 and 13 Gy, respectively. Analysis of dosimetric performance showed that GRS treatments are highly conformal, achieving steep dose gradients. The median imaging follow-up was 10.6 months. Volumetry of the treated targets demonstrated an early treatment effect, with either tumor volume reduction or stability for most tumors.
Conclusion: The early results of this prospective study, which enrolls patients undergoing GRS, show the efficacy and safety of the new self-shielding treatment platform. Due to the limited follow-up of this analysis, future studies including long-term outcome data are needed.
Keywords: ZAP-X; brain metastasis; gyroscopic radiosurgery; meningioma; radiosurgery; stereotactic radiosurgery; vestibular schwannoma.
Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved.